Reducing the impact of migraine on functioning: Results from the STRIVE trial, a phase 3, randomised, double-blind, placebo-controlled study of erenumab in patients with episodic migraine

被引：0
|
作者：
Buse, Dawn C. [1 ,2 ]
Lipton, Richard B. [1 ,2 ]
Mikol, Daniel D. [3 ]
Thach, Andrew V. [3 ]
Desai, Pooja [3 ]
Picard, Hernan [3 ]
Kubo, Yumi [3 ]
Hareendran, Asha [4 ]
Kawata, Ariane K. [5 ]
机构：
[1] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[2] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Evidera, London, England
[5] Evidera, Bethesda, MD USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P98
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Reducing the Impact of Migraine on Functioning: Results from the STRIVE Trial: A Phase 3, Randomized, Double-Blind Study of Erenumab in Subjects with Episodic Migraine
    Buse, Dawn C.
    Lipton, Richard B.
    Mikol, Daniel D.
    Thach, Andrew V.
    Desai, Pooja
    Picard, Hernan
    Kubo, Yumi
    Hareendran, Asha
    Kawata, Ariane K.
    CEPHALALGIA, 2017, 37 : 195 - 196
  • [2] Reducing impaired days: Results from the STRIVE trial, a phase 3, randomised, double-blind study of erenumab for episodic migraine
    Hareendran, Asha
    Buse, Dawn C.
    Lipton, Richard B.
    Bayliss, Martha S.
    Mikol, Daniel D.
    Revicki, Dennis A.
    Zhang, Feng
    Desai, Pooja
    Picard, Hernan
    Kawata, Ariane K.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [3] Reducing Impaired Days: Results from the STRIVE Trial, A Phase 3, Randomized, Double-Blind Study of Erenumab for Episodic Migraine
    Hareendran, Asha
    Buse, Dawn C.
    Lipton, Richard B.
    Bayliss, Martha S.
    Mikol, Daniel D.
    Revicki, Dennis A.
    Zhang, Feng
    Desai, Pooja
    Picard, Hernan
    Kawata, Ariane K.
    CEPHALALGIA, 2017, 37 : 275 - 276
  • [4] Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention: Primary results of the STRIVE trial
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel D.
    Lenz, Robert A.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [5] PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN MIGRAINE PREVENTION: PRIMARY RESULTS OF THE STRIVE TRIAL
    Goadsby, Peter J.
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel
    Lenz, Robert
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (05):
  • [6] A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB IN MIGRAINE PREVENTION: PRIMARY RESULTS OF THE ARISE TRIAL
    Dodick, David
    Ashina, Messoud
    Kudrow, David
    Lanteri-Minet, Michel
    Osipova, Vera
    Palmer, Kerry
    Picard, Hernan
    Mikol, Daniel D.
    Lenz, Robert A.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (05):
  • [7] Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention: primary results of the STRIVE Trial
    Goadsby, P. J.
    Reuter, U.
    Bonner, J.
    Broessner, G.
    Hallstrom, Y.
    Zhang, F.
    Sapra, S.
    Picard, H.
    Mikol, D.
    Lenz, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 117 - 117
  • [8] Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial
    Goadsby, Peter
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel
    Lenz, Robert
    NEUROLOGY, 2017, 89 (08) : E104 - E104
  • [9] Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial
    Goadsby, P. J.
    Reuter, U.
    Bonner, J.
    Broessner, G.
    Hallstrom, Y.
    Zhang, F.
    Sapra, S.
    Picard, H.
    Mikol, D. D.
    Lenz, R. A.
    HEADACHE, 2017, 57 : 128 - 129
  • [10] Patient-Reported Outcomes from the STRIVE Trial: A Phase 3, Randomized, Double-Blind Study of Erenumab in Subjects with Episodic Migraine
    Buse, D. C.
    Lipton, R. B.
    Hallstrom, Y.
    Reuter, U.
    Tepper, S. J.
    Zhang, F.
    Sapra, S.
    Picard, H.
    Mikol, D. D.
    Lenz, R. A.
    HEADACHE, 2017, 57 : 198 - 199
12345